Consistent with the prognostic role of WDR5 [24–27], we associated its expression with breast cancer progression and aggressiveness, by making use of a panel of cell lines and PDX models of metastatic tumors, the latter representing patients resistant to different lines of therapy. Here, WDR5 is linked to metastatic neoplasm.